137. Focal cortical dysplasia Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 14 Drugs : 10 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathways : 49

Drugs, Primary sponsors and Trial info (Enrollment year, Phase, Trial ID, Countries)
Blood and nasal swab sampling
   King's College Hospital NHS Trust
      2023   -   NCT06053671   United Kingdom
Classical ketogenic diet
   University College, London
      2014   -   NCT02261753   Austria;Belgium;Czech Republic;Czechia;France;Germany;Italy;Switzerland;United Kingdom;United States
Everolimus
   NYU Langone Health
      2014   Phase 2   NCT02451696   United States
   Yonsei University
      2018   Phase 2   NCT03198949   Korea, Republic of
Radiprodil
   GRIN Therapeutics, Inc.
      2024   Phase 1/Phase 2   NCT06392009   Australia;Belgium;Canada;Italy;Netherlands;Poland;Spain;United Kingdom
Radiprodil + CO-administered drugs
   GRIN Therapeutics, Inc.
      2025   Phase 1   NCT06975605   Australia
Radiprodil with carbamazepine
   GRIN Therapeutics, Inc.
      2025   Phase 1   NCT06965881   Australia
Radiprodil with itraconazole
   GRIN Therapeutics, Inc.
      2025   Phase 1   NCT06965881   Australia
Rapamune 1 MG/ML oral solution
   The Children's Memorial Health Institute
      -   Phase 2   EUCTR2021-006702-78-PL   Poland
Rapamune 1MG/ML oral solution
   The Children's Memorial Health Institute
      -   Phase 2   EUCTR2021-006702-78-PL   Poland
Sirolimus
   Hokkaido University Hospital
      2018   -   JPRN-UMIN000030962   Japan
   Hokkaido University Hospital Nishi-Niigata Chuo National Hospital National Center Hospital, NCNP Shizuoka Institute of Epilepsy and Neurological Disorders Okayama University Hospital
      2018   Phase 2   JPRN-UMIN000033504   Japan
   Kato Mituhiro
      2023   Phase 3   JPRN-jRCT2031230317   -
   Kato Mitsuhiro
      2019   Phase 2   JPRN-jRCTs031190157   -
   National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, NHO
      2017   Phase 2   JPRN-UMIN000030797   Japan
   Takahashi Yukitoshi
      2019   Phase 2   JPRN-jRCTs041190059   -